BiologicalDrug
Tralokinumab clinical trials
Also written CAT-354.
Keep track of what changes. Save the tralokinumab studies recruiting or about to start, and get an email each week — studies that open, close, add sites or post results.
Watch these studiesHow studies write it
Studies that test it under each name
Studies by the year they started
31 studies that test it; most in 2018 (6)
| Year | Studies |
|---|---|
| 2006 | 1 |
| 2008 | 2 |
| 2009 | 1 |
| 2010 | 1 |
| 2011 | 1 |
| 2012 | 3 |
| 2014 | 3 |
| 2015 | 2 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 6 |
| 2020 | 2 |
| 2022 | 2 |
| 2023 | 2 |
| 2026 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
- Asthma
- 12
Who runs them
Industry 27 · Other 4
LEO Pharma (12) · MedImmune LLC (9) · AstraZeneca (6) · Prof. Dr. Stephan Weidinger (1) · Emma Guttman (1) · University of California, San Francisco (1) · Psoriasis Treatment Center of Central New Jersey (1)
Often tested with
Tested in the same studies.
Triamcinolone (1) · Fluorouracil (1) · Calcipotriene (1) · Tapinarof (1) · Crisaborole (1) · Tacrolimus (1) · Adalimumab (1) · Etanercept (1)
Studies
Open first, then newest update. How each study uses tralokinumab is read from its arms, and is right about nine times in ten.
Testing it · 31
- Utilization of a Microdevice for Psoriasis and Atopic DermatitisNot yet recruitingPhase 4University of California, San FranciscoNCT07352566Written as Tralokinumab
- A 32-week Trial to Evaluate the Efficacy and Safety of Tralokinumab in Subjects With Moderate-to-severe Atopic Hand Eczema Who Are Candidates for Systemic TherapyCompletedPhase 3LEO PharmaNCT05958407Written as Tralokinumab
- Tralokinumab for Dupilumab FailuresTerminatedPhase 4Psoriasis Treatment Center of Central New JerseyNCT06773455Written as tralokinumab
- Tralokinumab Monotherapy for Children With Moderate-to-severe Atopic Dermatitis - TRAPEDS 1 (TRAlokinumab PEDiatric Trial no. 1)CompletedPhase 2LEO PharmaNCT05388760Written as Tralokinumab
- Efficacy and Safety of Tralokinumab Administered by an Autoinjector in Adults and Adolescents With Moderate to Severe Atopic Dermatitis (INJECZTRA)CompletedPhase 3LEO PharmaNCT05194540Written as Tralokinumab
- Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 1 (ECZema TRAlokinumab Trial no. 1)CompletedPhase 3LEO PharmaNCT03131648Written as Tralokinumab
- Tralokinumab in Combination With Topical Corticosteroids in Subjects With Severe Atopic Dermatitis - ECZTRA 7CompletedPhase 3LEO PharmaNCT03761537Written as Tralokinumab
- Tralokinumab Monotherapy for Moderate to Severe Atopic Dermatitis - ECZTRA 2 (ECZema TRAlokinumab Trial no. 2)CompletedPhase 3LEO PharmaNCT03160885Written as Tralokinumab
- Tralokinumab Monotherapy for Adolescent Subjects With Moderate to Severe Atopic Dermatitis - ECZTRA 6 (ECZema TRAlokinumab Trial no. 6).CompletedPhase 3LEO PharmaNCT03526861Written as Tralokinumab
- Long-term Extension Trial in Subjects With Atopic Dermatitis Who Participated in Previous Tralokinumab Trials - ECZTENDCompletedPhase 3LEO PharmaNCT03587805Written as Tralokinumab
- Vaccine Responses in Tralokinumab-Treated Atopic Dermatitis - ECZTRA 5 (ECZema TRAlokinumab Trial No. 5)CompletedPhase 2LEO PharmaNCT03562377Written as Tralokinumab
- Tralokinumab in Combination With Topical Corticosteroids in Japanese Subjects With Moderate-to-severe Atopic DermatitisCompletedPhase 3LEO PharmaNCT04587453Written as Tralokinumab
- Tralokinumab in Combination With Topical Corticosteroids for Moderate to Severe Atopic Dermatitis - ECZTRA 3CompletedPhase 3LEO PharmaNCT03363854Written as Tralokinumab
- Drug-drug Interaction Trial With Tralokinumab in Moderate to Severe Atopic Dermatitis - ECZTRA 4CompletedPhase 1LEO PharmaNCT03556592Written as Tralokinumab
- Effects of Tralokinumab Treatment of Atopic Dermatitis on Skin Barrier FunctionCompletedPhase 2Prof. Dr. Stephan WeidingerNCT04556461Written as Tralokinumab
- A Pilot Study of Tralokinumab in Subjects With Moderate to Severe Alopecia AreataCompletedPhase 2Emma GuttmanNCT02684097Written as Tralokinumab
- A Study to Evaluate the Safety of Tralokinumab in Adults and Adolescents With Uncontrolled AsthmaTerminatedPhase 3AstraZenecaNCT02902809Written as Tralokinumab open-label
- Phase 3 Study to Evaluate the Efficacy & Safety of Tralokinumab in Adults & Adolescents With OCS Dependent AsthmaCompletedPhase 3AstraZenecaNCT02281357Written as Tralokinumab
- Study to Evaluate Efficacy & Safety of Tralokinumab in Subjects With Asthma Inadequately Controlled on CorticosteroidsCompletedPhase 2AstraZenecaNCT02449473Written as Tralokinumab
- A Study of Tralokinumab When Delivered Subcutaneously at Different Flow Rates to Healthy VolunteersCompletedPhase 1MedImmune LLCNCT02085473Written as Tralokinumab 300 mg
Codes
What other systems call tralokinumab · ClinicalTrials.gg INT006111
- MeSH (NLM) C574065tralokinumabOne source NLM
- UNII (FDA) GK1LYB375ATRALOKINUMABConfirmed FDA, NLM, Wikidata
- RxNorm 2589225One source FDA
- Wikidata Q7833105TralokinumabConfirmed FDA, NLM, Wikidata
- NCI Thesaurus C152710TralokinumabOne source FDA
- DrugBank DB12169One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C574065 | tralokinumab | One source NLM |
| UNII (FDA) | GK1LYB375A | TRALOKINUMAB | Confirmed FDA, NLM, Wikidata |
| RxNorm | 2589225 | — | One source FDA |
| Wikidata | Q7833105 | Tralokinumab | Confirmed FDA, NLM, Wikidata |
| NCI Thesaurus | C152710 | Tralokinumab | One source FDA |
| DrugBank | DB12169 | — | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.